CFIA
NKGN

Cantor Fitzgerald Investment Advisors’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Cantor Fitzgerald Investment Advisors’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$2.47M Hold
255,000
– – 0.11% 120
2021
Q4 		$2.46M Buy
+255,000
New +$2.48M 0.15% 117

Other funds holding NKGN

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.62% 1-Year Est. Return
SCC
Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

Cantor Fitzgerald Investment Advisors's NKGN Position: Q1 2022 in Review

Cantor Fitzgerald Investment Advisors held its NKGen Biotech, Inc. Common Stock (NKGN) position steady in Q1 2022 at 255,000 shares worth $2.47M. The position accounts for 0.11% of the portfolio, ranked #120.

Cantor Fitzgerald Investment Advisors first reported a position in NKGN in Q4 2021 and has held it in 2 quarters since. 43 funds tracked by Wall St. Rank hold NKGN as of Q1 2022.

  • Cantor Fitzgerald Investment Advisors held 255,000 shares of NKGen Biotech, Inc. Common Stock worth $2.47M as of Q1 2022.
  • Cantor Fitzgerald Investment Advisors left its NKGen Biotech, Inc. Common Stock share count unchanged in Q1 2022.
  • NKGen Biotech, Inc. Common Stock made up 0.11% of Cantor Fitzgerald Investment Advisors's portfolio in Q1 2022, its #120 holding.
  • Cantor Fitzgerald Investment Advisors first reported a position in NKGen Biotech, Inc. Common Stock in Q4 2021 and has held it in 2 quarters since.
  • 43 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2022.

Based on Cantor Fitzgerald Investment Advisors's 13F filing for Q1 2022, filed 13 Apr 2022.